Systemic autoimmune diseases (SADs) are a heterogeneous group of pathologies characterized by dysregulation of immune system, which leads to the aberrant response of immune cells against autoantigens. SADs are associated with an increased risk of suffering cardiovascular (CV) events involving a complex interplay among traditional CV-risk factors, altered immune functions and disease activity. Numerous processes participate in the development of vascular pathologies including inflammation, oxidative stress, endothelial dysfunction, dyslipidemia, NETosis and apoptosis. The control and prevention of this comorbidity is crucial in the clinical management of these patients.
Despite the abundant evidence available regarding the main biological processes associated with the development of cardiovascular disease (CVD) in SADs over the last years, the molecular mechanisms underlying this pathogenic condition are still to be fully elucidated. The complete characterization of CVD in SADs at clinical and molecular levels will contribute to: i) the development of new therapeutic approaches; ii) the identification of novel biomarkers for diagnosis and prognosis; iii) the implementation of personalized clinical strategies. Coordinated studies involving the multidisciplinary interaction of patients, physicians, molecular scientists and bioinformaticians, among others, would ensure the achievement of these challenging goals.
The aim of this Research Topic is to publish Original Research and Review articles that may provide new insights related to CVD associated with SADs, focusing on, but not limited to, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Antiphospholipid Syndrome, Systemic Sclerosis and Sjögren’s Syndrome.
Specific Themes:
- Epidemiology of CVD associated with SADs
- Clinical biomarkers for monitoring CVD in SADS
- Prevention and Therapeutic management of CVD in SADs
- New molecular mechanisms associated with the pathogenesis of CVD in SADs
- Genetic and epigenetic mechanisms regulators of CVD in SADs
- Novel Biomarkers of CVD in SADs (transcriptomic, methylation, microRNAs, NETosis, metabolomics, lipidomics, etc)
- Bioinformatic approaches integrating multi-omics and machine learning
Systemic autoimmune diseases (SADs) are a heterogeneous group of pathologies characterized by dysregulation of immune system, which leads to the aberrant response of immune cells against autoantigens. SADs are associated with an increased risk of suffering cardiovascular (CV) events involving a complex interplay among traditional CV-risk factors, altered immune functions and disease activity. Numerous processes participate in the development of vascular pathologies including inflammation, oxidative stress, endothelial dysfunction, dyslipidemia, NETosis and apoptosis. The control and prevention of this comorbidity is crucial in the clinical management of these patients.
Despite the abundant evidence available regarding the main biological processes associated with the development of cardiovascular disease (CVD) in SADs over the last years, the molecular mechanisms underlying this pathogenic condition are still to be fully elucidated. The complete characterization of CVD in SADs at clinical and molecular levels will contribute to: i) the development of new therapeutic approaches; ii) the identification of novel biomarkers for diagnosis and prognosis; iii) the implementation of personalized clinical strategies. Coordinated studies involving the multidisciplinary interaction of patients, physicians, molecular scientists and bioinformaticians, among others, would ensure the achievement of these challenging goals.
The aim of this Research Topic is to publish Original Research and Review articles that may provide new insights related to CVD associated with SADs, focusing on, but not limited to, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Antiphospholipid Syndrome, Systemic Sclerosis and Sjögren’s Syndrome.
Specific Themes:
- Epidemiology of CVD associated with SADs
- Clinical biomarkers for monitoring CVD in SADS
- Prevention and Therapeutic management of CVD in SADs
- New molecular mechanisms associated with the pathogenesis of CVD in SADs
- Genetic and epigenetic mechanisms regulators of CVD in SADs
- Novel Biomarkers of CVD in SADs (transcriptomic, methylation, microRNAs, NETosis, metabolomics, lipidomics, etc)
- Bioinformatic approaches integrating multi-omics and machine learning
